BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12584031)

  • 1. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.
    Montagnani A; Gonnelli S; Cepollaro C; Campagna MS; Franci MB; Pacini S; Gennari C
    Bone; 2003 Jan; 32(1):15-9. PubMed ID: 12584031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
    Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
    Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
    Tucci JR; Bontha S
    Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
    Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
    Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ; Gunasekera RD
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous pamidronate therapy on Paget's disease of bone.
    Bombassei GJ; Yocono M; Raisz LG
    Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
    Ang G; Feiglin D; Moses AM
    Endocr Pract; 2003; 9(4):280-3. PubMed ID: 14561571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.
    Adami S; Braga V; Guidi G; Gatti D; Gerardi D; Fracassi E
    J Bone Miner Res; 2000 Mar; 15(3):599-604. PubMed ID: 10750576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
    Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
    Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose pamidronate in the management of resistant Paget's disease.
    Cundy T; Wattie D; King AR
    Calcif Tissue Int; 1996 Jan; 58(1):6-8. PubMed ID: 8825232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paget's disease of bone: five regimens of pamidronate treatment.
    Pepersack T; Karmali R; Gillet C; François D; Fuss M
    Clin Rheumatol; 1994 Mar; 13(1):39-44. PubMed ID: 8187442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
    Cantrill JA; Buckler HM; Anderson DC
    Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of Paget's disease with bisphosphonate pamidronate (AHPrBP, formerly APD)].
    Scharla SH; Grauer A; Ziegler R
    Klin Wochenschr; 1991 Jan; 69(1):25-30. PubMed ID: 2016845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
    Wilczek H
    Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
    Stewart GO; Gutteridge DH; Price RI; Ward L; Retallack RW; Prince RL; Stuckey BG; Kent GN; Bhagat CI; Dhaliwal SS
    Bone; 1999 Feb; 24(2):139-44. PubMed ID: 9951784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonate therapy of Paget's disease of bone with pamidronate].
    Grauer A; Klar B; Knaus J; Scharla SH; Ziegler R
    Med Klin (Munich); 1996 Jan; 91(1):14-9. PubMed ID: 8839196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE
    Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.